Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma

J Clin Oncol. 2023 May 20;41(15):2862-2864. doi: 10.1200/JCO.23.00057. Epub 2023 Mar 28.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Squamous Cell* / drug therapy
  • Carcinoma, Squamous Cell* / genetics
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Neoplasms* / genetics
  • Esophageal Squamous Cell Carcinoma* / pathology
  • Esophageal Squamous Cell Carcinoma* / therapy
  • Humans
  • Prognosis

Substances

  • B7-H1 Antigen